Observers concerned about the prospects for Bayer AG’s pharmaceutical operations once the big-selling heart drug Xarelto and blockbuster eye therapy Eylea lose patent protection will have been enthused by good news on Nubeqa and Kerendia, its two key growth-drivers for the rest of this decade and beyond.
Bayer's Faith In Pharma Pipeline Paying Off
Positive News For Nubeqa and Kerendia
The German major has presented the latest developments in the ongoing transformation of its pharmaceuticals business, starting with the prostate cancer therapy Nubeqa which Bayer believes will be a €3bn drug, way up on its earlier estimate of €1bn.
